Hormonal
High-dose GLP-1 receptor agonists (semaglutide 2.4 mg/week) and dual GLP-1/GIP agonists (tirzepatide 15 mg/week) produce substantial weight loss (>15% and >20% respectively) in non-diabetic obese individuals, with efficacy maintained over 2 years.
For non-diabetic individuals with obesity, weekly injections of semaglutide (2.4 mg) or tirzepatide (15 mg), combined with a reduced-calorie diet and exercise, can lead to 15-20% body weight loss over two years. Expect initial gastrointestinal side effects like nausea, which usually subside within a few months as the dose is gradually increased.
The STEP trial programme assessed the effect of a high dose of the GLP-1RA semaglutide (2.4 mg once weekly by subcutaneous injection: Weygovy) and typically noted about a 15% reduction in body weight during treatment periods up to 2 years in overweight and obese adults who did not have T2DM... The design of the SURMOUNT trial programme with the synthetic dual GLP-1R/GIPR agonist tirzepatide... typically reduced body weight by about 20% during treatment periods up to 2 years in overweight and obese adults who did not have T2DM
Why this rating
Based on multiple large-scale, randomized, placebo-controlled Phase 3 clinical trials (STEP 1-5, SURMOUNT-1, 3).
Source
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey et al. · Peptides · 2024
DOI 10.1016/j.peptides.2024.171149
More from this paper
- Triple agonists (GLP-1/GIP/Glucagon) like retatrutide achieve even greater weight loss (>24%) than dual agonists, likely due to the addition of glucagon receptor agonism which increases energy expenditure.Good
- Combination therapy of semaglutide (2.4 mg) and cagrilintide (2.4 mg) (CagriSema) produces weight loss (~15.6%) and HbA1c reduction (~2.2%) comparable to the highest dose of tirzepatide (15 mg) in patients with Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →